U.S. stocks punched higher Thursday as investors digested a stronger-than-expected monthly employment report amid rising numbers of new coronavirus cases.
NioCorp Developments Ltd. ("NioCorp" or the "Company") (TSX: NB; OTCQX: NIOBF) is pleased to announce the promotion of Scott Honan to Chief Operating Officer ("COO") of NioCorp, a new position. The promotion is effective immediately.
Historic numbers of background checks to purchase or possess a firearm were done in June, a trend in a year marked by uncertainty over the coronavirus pandemic, a subsequent economic recession, protests over racial injustice and calls to reduce police funding.
If you had bought Novavax (NASDAQ: NVAX) stock at the beginning of the year, you would be a happy investor right now. Shares of this biotech company have skyrocketed by almost 2,000% year to date, a rare feat even within the volatile biotech industry. Novavax has been able to achieve these returns thanks to its involvement in the hunt for a vaccine for COVID-19.
As we enter the second half of the year, pharma companies are still frantically engaged in the search for a COVID-19 vaccine. There are many companies in the mix, but it is not a level playing field, as big players are pitted against smaller names. At the onset of the pandemic, Novavax (NVAX) stood squarely in the latter camp. Facing pharma giants such as Pfizer, AstraZeneca and J&J, the small-cap biotech was at a disadvantage from the start. However, the vaccine specialist has become a force to be reckoned with. The incredible share gains (almost 1,855% year-to-date) which have pushed the market cap up to $4.6 billion, and various grants that have significantly bolstered the balance sheet, have positioned it as a real contender. However, it shouldn’t be forgotten that Novavax is still a ways away from presenting a solution to the public. Yet, according to H.C. Wainwright analyst Vernon Bernardino, Novavax could be well positioned to capitalize on possible future events. Following a virtual fireside chat with Novavax’s CFO, the 5-star analyst came away confident that the biotech can deliver on its promise. “With insights gained from our mini-conference that pointed to a CoV market that is likely a sustainable long-term market opportunity, and backed by a Coalition for Epidemic Preparedness Innovations (CEPI) commitment to invest up to $388 million that significantly de-risks clinical development of NVX-CoV2373, we believe Novavax’ capability to be a robust competitor against larger vaccine makers suggests the company could realize over $400 million in annual sales of NVX-CoV2373,” said Bernardino. Guiding the analyst’s thesis is the unfortunate fact that the coronavirus, or another virus closely related, will possibly rear its ugly head again sometime in the future. This means therapies will require “continued development.” Given the possibility SARS-CoV-2 could mutate, it is likely that “booster vaccinations, new vaccines against mutated SARS-CoV-2, as well as the availability of antiviral and antibody therapies, may be needed to prepare for future pandemics.” Novavax’s advantage in this case, the analyst argues, is its use of vaccine adjuvants, specifically Novavax’s proprietary Matrix-M adjuvant. Bernardino concluded, “In a situation where a significant percentage of the world’s 7 billion-plus population may need to be vaccinated, the potential of adjuvants to boost vaccine efficacy, and thus, be dose-sparing could be important if not enough CoV vaccine is available for global distribution. We look for the value of Matrix-M to continue to emerge in the months ahead.” All in all, Bernardino reiterated a Buy rating on NVAX, while giving the price target a significant boost – up from $50 to $101. Investors could be taking home a 28% gain, should Bernardino’s thesis play out in the year ahead. (To watch Bernardino’s track record, click here) It appears Bernardino’s fellow analysts agree. Consensus rates NVAX a Strong Buy, based on 4 Buys and 1 Hold. However, some feel the vaccine specialist has surged far enough for now, as the current average price target of $75.80 suggests shares could decline by 4% over the next 12 months. (See Novavax stock analysis on TipRanks)
Administrators at South African Airways (SAA) aim to publish a revised restructuring plan on July 7 incorporating some ideas from committees representing the airline's creditors and employees, the administrators' spokeswoman said on Thursday. The administrators published a restructuring plan for the struggling state-owned airline last month after repeated delays and months of wrangling with the government and trade unions. Louise Brugman, spokeswoman for SAA administrators Les Matuson and Siviwe Dongwana, said the airline's creditors' and employees' committees had submitted proposals for changes to the plan which were being discussed.
A U.S. House of Representatives committee unanimously backed a $741 billion defense bill late on Wednesday, setting the stage for a battle with President Donald Trump over naming military bases for Confederate generals and moving troops from Germany. The House Armed Services Committee approved its version of the annual National Defense Authorization Act, or NDAA, by 56-0 shortly before midnight. Because it is one of the few bills Congress passes every year, lawmakers use the NDAA as a vehicle for a wide range of policy provisions.
Read the full report: https://www.reportlinker.com/p05913678/?utm_source=PRN The Global Breast Cancer Liquid Biopsy Market is expected to grow from USD 247.29 Million in 2019 to USD 680.75 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 18.38%.Market Segmentation & Coverage:This research report categorizes the Breast Cancer Liquid Biopsy to forecast the revenues and analyze the trends in each of the following sub-markets:On the basis of Biomarker, the Breast Cancer Liquid Biopsy Market is studied across Cell-free DNA (cfDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs), and Other Circulating Biomarkers. On the basis of End-User, the Breast Cancer Liquid Biopsy Market is studied across Hospitals & Physician Laboratories and Reference Laboratories. On the basis of Geography, the Breast Cancer Liquid Biopsy Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Breast Cancer Liquid Biopsy Market including Biodesix, Inc., FLUXION BIOSCIENCES, GUARDANT HEALTH, INC, Isogen Life Science, and Thermo Fisher Scientific Inc.. FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Breast Cancer Liquid Biopsy Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D; activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Breast Cancer Liquid Biopsy Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Breast Cancer Liquid Biopsy Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Breast Cancer Liquid Biopsy Market?4. What is the competitive strategic window for opportunities in the Global Breast Cancer Liquid Biopsy Market?5. What are the technology trends and regulatory frameworks in the Global Breast Cancer Liquid Biopsy Market?6. What are the modes and strategic moves considered suitable for entering the Global Breast Cancer Liquid Biopsy Market?Read the full report: https://www.reportlinker.com/p05913678/?utm_source=PRN About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001
The "Relapsed or Refractory Mycosis Fungoides (MF) and Sézary Syndrome (SS) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Boycotting Facebook Inc. may be more cost-effective in elevating brand names and appealing to socially-conscious consumers for advertisers who were already looking to shave millions in ad spending, experts told MarketWatch amid a high-profile protest of the social-media platform.
Dealing with raw meat can be tricky and cooking it improperly can be deadly. Here are grilling safety tips for your socially-distanced July 4 cookout.
The Dow industrials soared 450 points Thursday on a strong jobs report. Tesla surged 9% on strong delivery numbers.
CoinPayments, the world's leading cryptocurrency payments processor, today announced its selection of Goodwin Procter LLP as its law firm of record. During the initial phase of the engagement, Goodwin will assist CoinPayments in its efforts to expand into regulated markets while driving increased transparency
By John Jannarone goPuff’s delivery volume rose 400% in the first half of 2020, according to sources goPuff now reaches 500 cities through over 200 distribution facilities Raised $1 billion from investors including Accel and SoftBank Vertical integration provides better customer experience and margins goPuff’s rapid expansion gives it head start and wide moat versus […]
(Bloomberg) -- Francois Bourdon has stepped down as global chief investment officer at Fiera Capital Corp., according to two people familiar with the situation, weeks after the money manager was forced to restrict redemptions in a large debt fund.Bourdon, who worked for the Montreal-based firm for more than 16 years, left the firm on June 30, one of the people said. He oversaw its investment policies and strategies as well as risk management.The move comes on the heels of a wider restructuring of Fiera, which managed C$167 billion ($123 billion) as of the end of April. As CIO, Bourdon also managed private financing strategies, global bonds and income funds -- including Fiera’s $1.1 billion Diversified Lending Fund, which put a limit on redemptions this spring after telling investors it was not positioned for a recession. The fund lends to the residential and commercial construction sector through limited partnerships and invested heavily in loans to housing projects.Bourdon managed the fund with two others, according fund documents, and the managers expressed confidence that bumps will be temporary and loans will be repaid. “The most likely scenario is that economic growth recovers at some point during the second half of 2020 and the strategy continues to produce attractive monthly returns,” they said in a written commentary to investors. Fiera has about 750 employees in North America and Europe. Its largest revenue line comes from handling institutional money.Restructuring ChargeLast month, the company said it would change its global management structure. Instead of being organized along geographic lines, it shifted to three operating groups: public markets, private markets and private wealth. The company said it expected to record severance and restructuring costs of C$19 million to C$21 million during the second quarter.Fiera shares were down 11 Canadian cents to C$9.39 as of 11:16 a.m. in Toronto. The shares are down nearly 20% this year. Bourdon will continue to do work for the firm as a consultant, the people said, asking not to be identified because the information is private.Nearly half of Fiera’s assets are in fixed income, though in recent years it has begun to build up a business managing funds in infrastructure and alternative assets.A representative for the firm did not reply to a request for comment. Bourdon declined to comment.(Updates with information on company restructuring starting in third paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
U.S. District Judge Anne Conway said that Donna Lorman's request for unlimited access to rides through Disney's FastPass line or at least 10 readmission passes was unnecessary and unreasonable, saying it was ripe for abuse.
A one-way ticket to nowhere Location: Taipei, Taiwan This airport is giving travel lovers the experience of going abroad without the flight ever taking off The fake itinerary includes passport control, security, and boarding for a plane on the tarmac which even has flight attendants Around 7,000 people applied to take part but only 60 won tickets (SOUNDBITE) (Mandarin) 38-YEAR-OLD EVENT PARTICIPANT, HSIAO CHUN-WEI, SAYING: "After receiving the confirmation that my number had been picked out to attend this event I thought, this is brilliant! And what's more my kid also wanted to come along to take a look at the plane. So we came. This really is a very special opportunity. And throughout this activity I've noticed, my son has been so, so happy." The airport hopes to show off its post-lockdown measures and encourage people to fly again soon
Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences Inc., has joined the CoVIg-19 Plasma Alliance to contribute to the acceleration of the development of a potential new therapy for COVID-19.
A flourishing first half for emerging market debt issuance is expected to continue, with worries among some investors about a risk of oversupply eased by Ukraine's cancellation of a $1.75 billion Eurobond. Higher-yield emerging market borrowers like Ukraine have been tempted back to the market by growing risk appetite after a glut of investment grade issues by Gulf governments and Israel in the immediate wake of the coronavirus crisis and oil price rout. Ukraine's plan was promptly aborted at the request of investors, sources said, after central bank governor Yakiv Smoliy unexpectedly resigned, in a reminder of the risks inherent in some emerging markets.
Iran’s financial and military support for Shi’ite proxy paramilitary groups in Iraq, a linchpin of its regional foreign policy, has been dramatically disrupted by the coronavirus pandemic and U.S. sanctions, according to people familiar with the matter. Interruptions caused by the virus, including border closings to prevent the spread of the disease, have drastically cut Tehran’s cash supplies to the militia groups in recent months, said three Iraqi paramilitary group commanders and a regional official familiar with Iran’s activities in Iraq.
Mark Mylod has been one of premium cable’s go-to directors for quite some time, having helmed episodes of Showtime’s “Shameless” and “The Affair,” as well as “Entourage” and “Game of Thrones” at HBO. Now Mylod is one of the key directors on “Succession,” handling episodes such as Season 2’s “Tern Haven” and the season finale […]